Isotretinoin: state of the art treatment for acne vulgaris
- 16 March 2010
- journal article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 8 (s1) , S47-S59
Abstract
Summary: Isotretinoin (13‐cisretinoic acid) is the most potent known inhibitor of sebum production. The multiple modes of action for isotretinoin, including suppression of sebaceous gland activity, normalization of the pattern of keratinization within the sebaceous gland follicle, inhibition of inflammation, reduction of growth ofPropionibacterium acnesin a secondary manner and, as currently shown, normalization of the expression of matrix tissue metalloproteinases and their inhibitors make this compound the single most effective in the treatment of severe recalcitrant nodulocystic acne, and in the prevention of acne scarring. Several generic formulations for oral use have recently been introduced, in addition to the brand formulations Roaccutane®and Accutane™ (Roche). This development, considering the high risk of teratogenicity associated with oral isotretinoin use, has led the European Commission and the European Medicines Agency (EMEA) to release a directive towards the harmonization of the Summary of Product Characteristics (SPC). This has similarities to US FDA regulations, a matter that caused the reaction of the Forum for the Improvement of Clinical Trials in Acne. Physician's experience, coupled with proper patient selection, dose adjustment or discontinuation of treatment, and routine monitoring for potential toxicity, has allowed the successful prevention and management of most adverse effects associated with isotretinoin.Keywords
This publication has 67 references indexed in Scilit:
- Inhibitors of Dipeptidyl Peptidase IV and Aminopeptidase N Target Major Pathogenetic Steps in Acne InitiationJournal of Investigative Dermatology, 2007
- Pharmaceutical quality of generic isotretinoin products, compared with RoaccutaneCurrent Medical Research and Opinion, 2006
- AcneNew England Journal of Medicine, 2005
- Zileuton, an Oral 5-Lipoxygenase Inhibitor, Directly Reduces Sebum ProductionDermatology, 2004
- 13-cis-Retinoic acid competitively inhibits 3α-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands?Biochemical and Biophysical Research Communications, 2003
- Uses and complications of isotretinoin therapyJournal of the American Academy of Dermatology, 2001
- Current Use and Future Potential Role of Retinoids in DermatologyDrugs, 1997
- Guidelines for optimal use of isotretinoin in acneJournal of the American Academy of Dermatology, 1992
- Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoinJournal of the American Academy of Dermatology, 1987
- Effect of retinoic acid on the proliferation and phagocytic capability of murine macrophage‐like cell linesJournal of Cellular Physiology, 1984